{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hepatitis-c/background-information/prognosis/","result":{"pageContext":{"chapter":{"id":"2eaad549-1687-5009-8092-731032ef4086","slug":"prognosis","fullItemName":"Prognosis","depth":2,"htmlHeader":"<!-- begin field d0ee3ac0-79e3-4768-8b3b-45a84e33ea6d --><h2>What is the prognosis?</h2><!-- end field d0ee3ac0-79e3-4768-8b3b-45a84e33ea6d -->","summary":"","htmlStringContent":"<!-- begin item c21c8a8d-1815-4fb8-9a91-a40300e3d819 --><!-- begin field 95b6646a-14ac-4732-9b53-214285f111a8 --><ul><li><strong>The long-term prognosis of hepatitis C virus (HCV) infection varies greatly between people and depends on the severity of liver fibrosis. </strong>Symptoms can take decades to occur. </li><li>Risk factors for a poor prognosis and <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-c/background-information/complications/\">complications</a> include [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">SIGN, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">Ahmad, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BASHH, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">PHE, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">PHE, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">WHO, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">BMJ, 2019</a>]:<ul><li>HCV genotype — genotypes 1, 4, 5, and 6 are less responsive to antiviral treatments than genotypes 2 and 3.</li><li>Infection at an older age — after 40 years of age, the likelihood of a successful response to treatment reduces by about 5% per decade.</li><li>Men are more likely to progress to cirrhosis than women.</li><li>Black African American and Hispanic people have lower sustained viral response rates with antiviral treatments than white and Asian people.</li><li>Co-infection with hepatitis A, and/or hepatitis B virus.</li><li>Co-infection with HIV.</li><li>Body mass index greater than 25 kg per m<sup>2</sup><strong> </strong>— associated with an increased risk of hepatic steatosis, which may lead to more severe fibrosis.</li><li>Smoking — an independent risk factor for hepatitis and fibrosis.</li><li>High alcohol intake.</li><li>Immunosuppression due to any cause — increased risk of developing cirrhosis or hepatocellular carcinoma [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-c/references/\">WHO, 2018</a>].</li></ul></li></ul><!-- end field 95b6646a-14ac-4732-9b53-214285f111a8 --><!-- end item c21c8a8d-1815-4fb8-9a91-a40300e3d819 -->","topic":{"id":"a0ad57e4-0817-5b1a-9292-791ffa142703","topicId":"55070782-69db-4c7d-9e54-4da85ba4447b","topicName":"Hepatitis C","slug":"hepatitis-c","lastRevised":"Last revised in April 2020","chapters":[{"id":"e461354a-b186-5681-bc32-8cb96b08ae6b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8fa52488-05cf-5879-a691-c723a1430a1f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6d95b11c-1fc9-5914-9218-3de2e896a24f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"1d7e82a7-43ee-5524-b888-82cc0dff9059","slug":"changes","fullItemName":"Changes"},{"id":"64c4c883-1cd3-543b-8c3e-44ef84da58ac","slug":"update","fullItemName":"Update"}]},{"id":"939e5b5f-4d63-5220-a24d-332b6fc2cdde","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"27fa7468-2569-5880-ad98-f0c2a205677f","slug":"goals","fullItemName":"Goals"},{"id":"bb21c10e-b9bb-5e53-b00d-76f2175ac2a6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8743e312-a175-57be-ace4-aa2951fd7c6d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1d0624de-065c-5696-bc52-cd0a3fc96ff0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"652c4849-e314-5c2f-9aee-813e3412e330","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"95ff6fef-b360-5a40-ba6d-d511e9cbea9e","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29bbbad3-26aa-5e9b-9381-9e82e2083ea1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ca0ed038-00d4-53b1-a0ec-0ee36dec9b4c","slug":"definition","fullItemName":"Definition"},{"id":"f4152d7e-511b-5b64-a7b0-fd3bbe90529e","slug":"transmission","fullItemName":"Transmission"},{"id":"56254cb4-0f61-544c-b3a3-46c8f0148e60","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fc3580a0-4415-5d71-b15e-b2d8b421e2c0","slug":"complications","fullItemName":"Complications"},{"id":"2eaad549-1687-5009-8092-731032ef4086","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"2ed6aea7-6c05-59b0-aa47-c293676c65b3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b827a0b9-4038-5046-bb7f-fd4b2965792d","slug":"who-to-screen-test","fullItemName":"Who to screen/test"},{"id":"415719a5-bfb8-5d93-9424-f5ce2b555354","slug":"how-to-test","fullItemName":"How to test"}]},{"id":"aa46d3c2-4a6e-544f-b6ad-e977b30cd44f","fullItemName":"Management","slug":"management","subChapters":[{"id":"70d87857-70c0-5a71-9e6b-8af6bcd3c53f","slug":"active-hepatitis-c-infection","fullItemName":"Scenario: Active hepatitis C infection"}]},{"id":"2a3a4ee7-054e-56d4-b866-d77b58228f83","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4097b54c-c716-53b0-8c01-d19a7b1efc90","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2e231f49-1646-5ad9-afbe-287aed9b553a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b0b10486-472e-53a7-8975-8005079c99ae","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"54258242-86fa-5282-aedd-bdcd1f636a6f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"02b519b7-6884-5329-b15d-752976d77af7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ccf574ec-19fa-5d3c-90f6-3a1468826262","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6765ac6b-398f-56e9-b9cc-2df0a4010bbd","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"29bbbad3-26aa-5e9b-9381-9e82e2083ea1","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}